Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of mavacamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy
MOH_2022-12-22_012251Phase 3Active, not recruiting
- Sponsor
- MyoKardia
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing mavacamten with placebo comparator (2 arms). Primary endpoints: Patient-reported health status at 52 weeks and Exercise capacity at 52 weeks. Started Nov 2022; status: active, not recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on MOH_2022-12-22_012251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-22_012251.